Loading...
NuVasive, Inc.
NUVA•NASDAQ
Healthcare
Medical - Devices
$39.75
$-0.91(-2.24%)

Financial performance has remained strong, with revenue growing from $295.28M in Q3 2022 to $317.79M in Q2 2023. Gross profit continued to perform well, with margins at 72% in the latest quarter. Operating income reached $35.80M in Q2 2023, holding a steady 11% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $61.22M. Net income rose to $7.36M, keeping EPS at $0.14. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan